TACSTD2 and breast carcinoma: Conversely, TROP2 overexpression in HR+ breast cancer is more subdued but prominently pronounced in HER2+ breast cancer, suggesting a potential avenue for combination therapies targeting both TROP2 and HER2 (13, 18, 42).